According to Dizhe Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 4.770 billion yuan, an increase of 713.50%; net profit attributable to shareholders of listed companies was 3,639 billion yuan, turning a loss into a profit; deducting non-net profit of 3.612 billion yuan; and R&D investment of 593 million yuan, a year-on-year decrease of 7.91%. Quarterly revenue for the third quarter of 2026 was 4.247 billion yuan, up 1736.09% year on year; net profit to mother was 3.849 billion yuan. The increase in performance was mainly due to a global licensing agreement with AstraZeneca on Schwarzer®. The $600 million down payment confirmed revenue during the reporting period. The application for marketing of Schwarzer® for new indications has been accepted by the US FDA, and several research pipelines are progressing steadily.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.